BPC-157, or Body Protecting Compound-157, is a 15-amino-acid peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) isolated from gastric juices.[1][2] It was first identified in the 1990s as part of research into cytoprotective agents that safeguard the gastrointestinal (GI) tract from damage.[3] Unlike many peptides, BPC-157 is highly stable in acidic environments, allowing for oral administration without significant degradation.[4] In compounding pharmacies, BPC-157 is often prepared as capsules, injectables, or topical formulations
Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinsons disease
Inflammatory skin diseases Various inflammatory skin diseases are attributed to the disruption of the skin barrier and aberrant structural components [61], and ferroptosis actively affects the epidermal barrier and skin homeostasis
10.1152/ajpheart.01323.2008 Am
Treatment is ongoing, so a year comprises 3-4 cycles
F., Xing, J